Brief: Biostage Activated Mayo Clinic As The First Site For Clinical Trial In Severe Esophageal Disease
18/07/2023 14:15
July 18 (Reuters) - Biostage Inc BSTG.PK :
* BIOSTAGE ACTIVATED MAYO CLINIC AS THE FIRST SITE FOR
CLINICAL
TRIAL IN SEVERE ESOPHAGEAL DISEASE
Source text for Eikon: ID:nPn6nk0qha
Further company coverage: BSTG.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Harvard Apparatus Regenerative Technology
See all newsBrief: Harvard Apparatus Regenerative Technology Announces Strategic Collaboration With Children’S Hospital Capital Institute Of Pediatrics In Beijing, China To Advance Treatment For Esophageal Atresia
Brief: Biostage Activated Mayo Clinic As The First Site For Clinical Trial In Severe Esophageal Disease
Brief: Biostage Amends CEO Employment Agreement
Brief: Biostage Inc Files For Firm Commitment Public Offering Of 1.03 Million Units - SEC Filing
Brief: Biostage Announces Appointment Of New Chief Financial Officer